newsfilter
← Latest News
GlobeNewswire·

Compass Therapeutics Reports 2026 First Quarter Financial Results and Provides Corporate Update

As recently announced, tovecimig (DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel demonstrated a highly statistically significant improvement in progression-free survival (PFS) versus paclitaxel alone